Therapy-related myeloid neoplasms: when genetics and environment collide.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28835720.
- Also identified by DOI 10.1038/nrc.2017.60 and PMC identifier 5946699.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Therapy-related myeloid neoplasms (t-MN) arise as a late effect of chemotherapy and/or radiation administered for a primary condition, typically a malignant disease, solid organ transplant or autoimmune disease. Survival is measured in months, not years, making t-MN one of the most aggressive and lethal cancers. In this Review, we discuss recent developments that reframe our understanding of the genetic and environmental aetiology of t-MN. Emerging data are illuminating who is at highest risk of developing t-MN, why t-MN are chemoresistant and how we may use this information to treat and ultimately prevent this lethal disease.
Medical subject headings
- Chromosome Aberrations
- Gene-Environment Interaction
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- Neoplasms, Second Primary